Anteo Diagnostics Limited engages in developing, commercializing, manufacturing, and distributing products for the life sciences research, in-vitro diagnostics, energy, and medical device markets primarily in Australia. Its principal technology products include AnteoCoat, which is applicable to the energy sector in lithium-ion batteries; AnteoBind that is applicable to point of care, in vitro, and life science diagnostic sectors; and AnteoRelease, which is applicable in the medical technology sector comprising implants for infectious diseases. The company also manufactures and sells in vitro diagnostic tests. Anteo Diagnostics Limited has a collaboration with Sona Nanotech Inc. to co-develop new products that have the potential to speed up the development and improve the performance of lateral flow immunoassays. The company was formerly known as Biolayer Corporation Limited and changed its name to Anteo Diagnostics Limited in November 2008. Anteo Diagnostics Limited is based in Eight Mile Plains, Australia.
Industry, Sector and Symbol
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 7 3219 0085
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$276,313.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Anteo Diagnostics (ASX:ADO) Frequently Asked Questions
What is Anteo Diagnostics' stock symbol?
Anteo Diagnostics trades on the ASX under the ticker symbol "ADO."
How were Anteo Diagnostics' earnings last quarter?
Anteo Diagnostics Ltd (ASX:ADO) announced its quarterly earnings results on Wednesday, February, 27th. The company reported $0.00 earnings per share for the quarter. View Anteo Diagnostics' Earnings History.
Has Anteo Diagnostics been receiving favorable news coverage?
Media stories about ADO stock have trended extremely negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Anteo Diagnostics earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Anteo Diagnostics.
Who are some of Anteo Diagnostics' key competitors?
Some companies that are related to Anteo Diagnostics include Medica Group (MGP), Imricor Med SYS Cdi 1:1 US Person Prohibited Excluding QIB (IMR), Hamilton Thorne (HTL), Cyclopharm (CYC), Advanced Oncotherapy (AVO), Electromed (ELMD), Electromed (ELMD), Kromek Group (KMK), MRI Interventions (MRIC), Patient Home Monitoring (PTQ), REVA Medical (RVA), Impedimed (IPD), Avacta Group (AVCT), EMvision Medical Devices (EMV) and Protech Home Medical (PHM).
What other stocks do shareholders of Anteo Diagnostics own?
Who are Anteo Diagnostics' key executives?
Anteo Diagnostics' management team includes the folowing people:
- Mr. Christopher Parker, Chief Exec. Officer
- Dr. N. Joe Maeji Ph.D., Founder & Chief Scientific Officer
- Mr. Duncan Patrick Cornish ACA, CFO & Company Sec. (Age 52)
- Mr. Julien Francis McInally B.Bus, MBA, CPA, Company Sec. & CFO (Age 47)
- Dr. Charlie Huang, Head of R&D
What is Anteo Diagnostics' stock price today?
One share of ADO stock can currently be purchased for approximately A$0.03.
How big of a company is Anteo Diagnostics?
What is Anteo Diagnostics' official website?
How can I contact Anteo Diagnostics?
The company can be reached via phone at 61 7 3219 0085.
MarketBeat Community Rating for Anteo Diagnostics (ASX ADO)
MarketBeat's community ratings are surveys of what our community members think about Anteo Diagnostics and other stocks. Vote "Outperform" if you believe ADO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADO will underperform the S&P 500 over the long term. You may vote once every thirty days.
